Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte precursor cell | 4 studies | 26% ± 7% | |
| luminal hormone-sensing cell of mammary gland | 4 studies | 22% ± 7% | |
| GABAergic neuron | 3 studies | 38% ± 2% | |
| club cell | 3 studies | 28% ± 10% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 4452.69 | 245 / 245 | 88% | 49.69 | 440 / 502 |
| breast | 100% | 3352.80 | 457 / 459 | 79% | 166.21 | 883 / 1118 |
| pancreas | 88% | 2187.64 | 289 / 328 | 60% | 11.39 | 107 / 178 |
| brain | 74% | 351.43 | 1946 / 2642 | 70% | 13.73 | 494 / 705 |
| bladder | 95% | 4173.95 | 20 / 21 | 42% | 18.07 | 211 / 504 |
| uterus | 99% | 1482.89 | 168 / 170 | 26% | 6.01 | 119 / 459 |
| skin | 72% | 848.34 | 1304 / 1809 | 44% | 15.69 | 208 / 472 |
| stomach | 100% | 2611.79 | 359 / 359 | 8% | 0.71 | 24 / 286 |
| intestine | 99% | 1562.46 | 961 / 966 | 8% | 0.86 | 40 / 527 |
| adipose | 100% | 2142.54 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 54.27 | 1 / 1 |
| esophagus | 89% | 581.67 | 1289 / 1445 | 5% | 0.46 | 9 / 183 |
| lung | 63% | 257.06 | 362 / 578 | 30% | 4.97 | 345 / 1155 |
| spleen | 89% | 661.28 | 215 / 241 | 0% | 0 | 0 / 0 |
| thymus | 71% | 276.98 | 462 / 653 | 13% | 1.35 | 76 / 605 |
| adrenal gland | 54% | 200.65 | 140 / 258 | 2% | 0.18 | 4 / 230 |
| muscle | 56% | 303.03 | 447 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 46% | 186.59 | 618 / 1335 | 0% | 0 | 0 / 0 |
| heart | 43% | 214.31 | 374 / 861 | 0% | 0 | 0 / 0 |
| kidney | 22% | 107.07 | 20 / 89 | 6% | 1.07 | 53 / 901 |
| ovary | 9% | 51.83 | 17 / 180 | 9% | 0.89 | 38 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 13% | 6.75 | 6 / 45 |
| liver | 1% | 3.69 | 3 / 226 | 6% | 1.49 | 24 / 406 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.17 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007165 | Biological process | signal transduction |
| GO_0005615 | Cellular component | extracellular space |
| GO_0009986 | Cellular component | cell surface |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005509 | Molecular function | calcium ion binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0008289 | Molecular function | lipid binding |
| Gene name | SCUBE2 |
| Protein name | Signal peptide, CUB domain and EGF like domain containing 2 Signal peptide, CUB and EGF-like domain-containing protein 2 (Protein CEGP1) (Scube/You) |
| Synonyms | CEGP1 |
| Description | FUNCTION: Lipid-binding protein required for SHH long-range signaling by binding to the dually lipid-modified SHH (ShhNp) and by promoting ShhNp mobilization, solubilization and release from the cell membrane . Acts by enhancing the proteolytic processing (shedding) of the lipid-modified N- and C- terminal of ShhNp at the cell surface . Synergizes with DISP1 to increase SHH secretion . Probable cell surface coreceptor for VEGFR2 involved in VEGFR2-mediated angiogenesis . . |
| Accessions | ENST00000519788.6 H0YEI5 H0YDN3 H0YD28 ENST00000520467.5 [Q9NQ36-2] ENST00000531429.1 H0YEB3 A0A3B3ISZ7 ENST00000309263.7 [Q9NQ36-1] ENST00000528651.1 ENST00000649792.2 ENST00000450649.6 [Q9NQ36-3] Q9NQ36 ENST00000519202.1 |
